Benzinga | Aug 9, 2021 07:35AM EDT

Intra-Cellular Therapies Q2 EPS $(0.85) Misses $(0.80) Estimate, Sales $20.05M Beat $19.44M Estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.80) by 6.25 percent. This is a 11.46 percent increase over losses of $(0.96) per share from the same period last year. The company reported quarterly sales of $20.05 million which beat the analyst consensus estimate of $19.44 million by 3.12 percent. This is a 951.21 percent increase over sales of $1.91 million the same period last year.